DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Fexaramine
Fexaramine
Bile Acid Receptor Farnesoid X Receptor: a Novel Therapeutic Target for Metabolic Diseases
Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease
Evolution of the Bile Salt Nuclear Receptor FXR in Vertebrates
Molecular Tuning of Farnesoid X Receptor Partial Agonism
Farnesoid X Receptor an Important Factor in Blood Glucose Regulation
G Protein-Coupled Receptors As Potential Targets for Nonalcoholic Fatty Liver Disease Treatment
Bile Acids and Oxysterols As Pivotal Actors Controlling Metabolism
Elucidating the Mechanism Behind the Lipid-Raising Effect of Cafestol Boekschoten, Mark, Vincent
The Concise Guide to PHARMACOLOGY 2015/16: Nuclear Hormone Receptors
Identification of a Potent Synthetic FXR Agonist with an Unexpected Mode of Binding and Activation
Role of TMEM141 in Cholesterol Metabolism
Discovery, Optimization, and Evaluation of Non-Bile Acid FXR/TGR5 Dual Agonists
Hydroxycholesterol Induces the Expression of The
) (51) International Patent Classification: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, I
Nuclear Receptor Metabolism of Bile Acids and Xenobiotics: a Coordinated Detoxification System with Impact on Health and Diseases
Expression and Activation of the Farnesoid X Receptor in the Vasculature
And Atg7f/F Mice [2] Had Been Reported in Previous Studies
Bioactive Compound Library Plus (96-Well)
Top View
Gut-Pancreas-Liver Axis As a Target for Treatment of NAFLD/NASH
Fxr Agonists Induce Distinct H-12 Structural States
On the Pharmacology of Farnesoid X Receptor Agonists: Give Me an “A”,Like in “Acid”
Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation S
Disease Associations of Primary Bile Acid Diarrhoea and Investigations Into Potential Treatments and a Possible Metabolic Syndrome of Low Fibroblast Growth Factor 19
© 2018 Justin Douglas Schumacher ALL RIGHTS RESERVED
Nuclear Hormone Receptors
The Therapeutic Landscape of Non- Alcoholic Steatohepatitis
Fatty Liver Disease (Nafld/Nash)
Farnesoid X Receptor Is an Exciting New Perspective Target for Treatment of Diverse Pathological Disorders: Review
WO 2017/117158 Al 6 July 2017 (06.07.2017) W P O P C T
Fxr Fxr; Nr1h4
The Concise Guide to Pharmacology 2019/20
Bile Acids in the Pathogenesis and Treatment of NASH
Theabrownin from Pu-Erh Tea Attenuates Hypercholesterolemia Via Modulation of Gut Microbiota and Bile Acid Metabolism
Farnesoid X Receptor Agonist Decreases Lipid Accumulation by Promoting Hepatic Fatty Acid Oxidation in Db/Db Mice
Bile Acids Mediated Potential Functional Interaction Between FXR
Bile Acid Based Therapeutics for Children and Adults